Switching between Epoetins: A Practice in Support of Biosimilar Use

BioDrugs

Volumn 30, Issue 1, 2016, Pages 27-32

  D'Amore, Carmen ^a   Da Cas, Roberto ^a   Rossi, Mariangela ^b   Traversa, Giuseppe ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Unit for Pharmaceutical Governance   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; BIOSIMILAR AGENT; ERYTHROPOIETIN;

AGED; ARTICLE; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ITALY; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOSIMILAR PHARMACEUTICALS; DRUG SUBSTITUTION; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; ITALY; MALE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84957433088     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0155-0     Document Type: Article

References (11)

1. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins. (EMEA/CHMP/BMWP/301636/2008). 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/04/WC500089474.pdf. Accessed 5 Aug 2015.
2. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473-85.
3. Wiȩcek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther. 2010;27:941-52.
4. AIFA position paper. I farmaci biosmilari. 2013. http://www.agenziafarmaco.gov.it/sites/default/files/AIFA-POSITION-PAPER-FARMACI-BIOSIMILARI.pdf. Accessed 5 Aug 2015.
5. Farmaci biosimilari: sicurezza, efficacia, omogeneità di trattamento e corretta informazione. Un Manifesto dei diritti dei pazienti. 2014. http://www.amrer.it/download-documenti/manifesto-farmaci-biosimilari.pdf. Accessed 17 Dec 2015.
6. Pani L, Montilla S, Pimpinella G. Bertini Malgarini R. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opin Biol Ther. 2013;13:1343-6.
7. Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V, et al. How much are biosimilars used in southern Italy? A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011. BioDrugs. 2012;26:113-20.
8. La Vecchia C, Franceschi S, Apolone G. Drug distribution and expenditure: the issue of epoetin in Italy. Eur J Public Health. 2003;13:367.
9. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009-2013. BioDrugs. 2015;29:275-84.
10. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23:3731-7.
11. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol. 2011;86:277-88.